

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT8147670

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
LUCIRA HEALTH, INC.	08/26/2023

RECEIVING PARTY DATA

Name:	PFIZER INC.
Street Address:	66 HUDSON BOULEVARD EAST
City:	NEW YORK
State/Country:	NEW YORK
Postal Code:	10001-2192

PROPERTY NUMBERS Total: 35

Property Type	Number
Application Number:	15306240
Application Number:	16359913
Application Number:	16894694
Application Number:	18111791
Application Number:	61983687
Application Number:	15481349
Application Number:	62307867
Application Number:	17342533
Application Number:	16081793
Application Number:	62307876
Application Number:	17393398
Application Number:	16081799
Application Number:	62307886
Application Number:	17677999
Application Number:	16081802
Application Number:	18364401
Application Number:	16155829
Application Number:	17364773
Application Number:	62307881
Application Number:	16081800

PATENT

Property Type	Number
Application Number:	29674581
Application Number:	29759253
Application Number:	29674582
Application Number:	16185314
Application Number:	17962324
Application Number:	62558815
Application Number:	16722475
Application Number:	62814143
Application Number:	17436903
Application Number:	63075086
Application Number:	18024245
Application Number:	63351427
Application Number:	29736854
Application Number:	29733684
Application Number:	29835658

CORRESPONDENCE DATA

Fax Number: (617)523-1231

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 617-570-1000

Email: khoward@goodwinlaw.com, KMubyana@goodwinlaw.com,
US-PatentBos@goodwinlaw.com

Correspondent Name: GOODWIN PROCTER LLP

Address Line 1: 100 NORTHERN AVENUE

Address Line 4: BOSTON, MASSACHUSETTS 02210

ATTORNEY DOCKET NUMBER:	DSS (US)
NAME OF SUBMITTER:	KUWABO MUBYANA
SIGNATURE:	/Kuwabo Mubyana/
DATE SIGNED:	09/03/2023

Total Attachments: 6

source=Lucira_Assignments_Schedule_A#page1.tif

source=Lucira_Assignments_Schedule_A#page2.tif

source=Lucira_Assignments_Schedule_A#page3.tif

source=Lucira_Assignments_Schedule_A#page4.tif

source=Lucira_Assignments_Schedule_A#page5.tif

source=Lucira_Assignments_Schedule_A#page6.tif

INVENTIONS AND PATENT RIGHTS ASSIGNMENT

This Inventions and Patent Rights Assignment (this "Assignment") is by and between **Lucira Health, Inc.**, a corporation and having a business address at 1315 63rd Street, Emeryville, California 94608, USA ("Assignor"), and **Pfizer Inc.**, a corporation having a usual place of business at 66 Hudson Boulevard East, New York, NY 10001-2192, USA ("Assignee").

WHEREAS, Assignor owns the entire right, title and interest in all inventions and improvements that are disclosed in the attached **Schedule A**; and

WHEREAS, Assignor now wishes to assign the Inventions and Patent Rights to Assignee, and Assignee desires to acquire the Inventions and Patent Rights from Assignor.

NOW, THEREFORE, in consideration of the mutual covenants and promises contained herein, and for other good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, Assignor and Assignee hereby agree as follows:

1. Assignor does hereby sell, assign, convey and transfer unto Assignee and its successors, assigns, and legal representatives, Assignor's entire right, title and interest, which Assignee accepts, in and throughout the world in and to the Inventions, together with Assignor's entire right, title and interest, which Assignee accepts, in and to the Patent Rights and such other patent applications and patents based thereon and as may issue thereon or claim priority under United States law or international or foreign convention, including but not limited to non-provisionals, continuations, divisionals, continuations-in-part, reissues, reexaminations, extensions, and substitutions of patents and patent applications within the Patent Rights or such other patents and patent applications based thereon, and any right, title and interest Assignor may have in applications to which the Patent Rights claim priority; and the right to claim priority to the Patent Rights and such other patent applications and patents based thereon; the Inventions and the Patent Rights and such other patent applications and patents based thereon to be held and enjoyed by Assignee for its own use and behalf and for its successors, assigns and legal representatives, to the full end of the term for which said patents may be granted as fully and entirely as the same would have been held by Assignor had this Assignment not been made; and Assignor hereby conveys all of its rights arising under or pursuant to any and all United States laws and foreign and international agreements, treaties or laws relating to the protection of industrial property by filing any such applications for patent, including but not limited to any cause(s) of action and damages accruing prior to this Assignment, including all rights to exclude others from practicing the claimed invention(s) and all rights to seek any and all remedies in law or equity, including damages and injunctive relief, for past, present, and future infringement. Assignor hereby acknowledges that this Assignment, being of Assignor's entire right, title and interest in and to the Inventions and the Patent Rights carries with it the right in Assignee to apply for and obtain from competent authorities in all countries of the world any and all patents by attorneys and agents of Assignee's selection and the right to procure the grant of all patents to Assignee in its own name as assignee of Assignor's entire right, title and interest therein.

2. Assignor hereby represents, warrants, and covenants to Assignee, its successors, assigns and legal representatives, that at the time of execution of this Assignment, except for any rights, titles and/or interests that have arisen to Assignee under law or that have already been

transferred to Assignee, that Assignor has not made and will not hereafter make any assignment, contract, grant, mortgage, license, or other agreement and/or understanding affecting and/or conflicting with the rights, titles, and interests conveyed herein.

3. Assignor hereby further agrees for itself and its successors, assigns, agents, and legal representatives to execute upon request any other lawful documents and likewise to perform any other lawful acts which may be deemed necessary to secure fully the Patent Rights and Inventions and such other patent applications and patents based thereon to Assignee, its successors, assigns, and legal representatives, as well as to third parties at the request of Assignee including the execution of documents (including, without limitation, petitions, specifications, oaths, assignments, disclaimers, declarations and affidavits) relating to non-provisional, substitution, continuation, divisional, reissue, reexamination, or corresponding foreign or international patent applications within or based on the Patent Rights, as requested by Assignee, and generally do everything possible to aid Assignee, its successors, assigns and legal representatives to obtain, record, maintain, and enforce full protection for the Inventions in all countries, but in each instance at Assignee's reasonable expense.

4. Assignor hereby further agrees to provide documentary evidence and statements or testimony in any interference, derivation, or post-grant proceeding, or other proceeding in which any of the Patent Rights and/or Inventions and/or such other patent applications and patents based thereon may be involved.

5. Assignor does hereby authorize the Director of the United States Patent and Trademark Office, and the appropriately empowered officials of all other governments, to record the Patent Rights, and such other patent applications and patents based thereon, and title thereto as the property of Assignee, its successors, assigns, or legal representatives in accordance with the terms of this instrument.

6. Assignor does hereby further authorize and request the Director of the United States Patent and Trademark Office, and the appropriately empowered officials of all other governments, to issue patents as shall be granted upon the Patent Rights, or such other patent applications based thereon, to Assignee, its successors, assigns, or legal representatives.

7. Assignee and Assignor also agree that multiple copies of this Assignment may be executed, each of which shall be deemed an original, and each of which shall be valid and binding upon Assignee and Assignor.

[Remainder of page intentionally left blank]

IN WITNESS WHEREOF, Assignor and Assignee have caused this Assignment to be executed by their duly authorized representatives as of the date(s) set forth below.

ASSIGNOR:

Lucira Health, Inc.

26 Aug 2023
Date

[Signature]
Name: Erik T. Engelson
Title: President & CEO

WITNESS:

26 August, 2023
Date

[Signature]
Signature
Name of Witness: Joseph S. Andresen

[Remainder of page intentionally left blank]

Signature Page of Patent Rights Assignment
between Lucira Health, Inc. and Pfizer Inc.

ASSIGNEE: **Pfizer Inc.**

Signature:

Name:

Title:


John A. Wichtowski

Assistant General Counsel

[Remainder of page intentionally left blank]

Signature Page of Patent Rights Assignment
between Lucira Health, Inc. and Pfizer Inc.

SCHEDULE A

Attorney Docket No.	Title	Application No.	Filing Date	Patent No.
31210-28770/US	Colorimetric Detection of Nucleic Acid Amplification	15/306240	24-Oct-2016	10253357
DSS-001C1	Colorimetric Detection of Nucleic Acid Amplification	16/359913	20-Mar-2019	10724079
DSS-001C2	Colorimetric Detection of Nucleic Acid Amplification	16/894694	05-Jun-2020	11584957
DSS-001C3	Colorimetric Detection of Nucleic Acid Amplification	18/111791	20-Feb-2023	
DSS-001PR	Colorimetric Detection of Nucleic Acid Amplification	61/983687	24-Apr-2014	
31210-34272/US	Image-Based Disease Diagnostics Using a Mobile Device	15/481349	06-Apr-2017	10146909
31210-31102/US	Systems and Methods for Performing Biological Assays	62/307867	14-Mar-2016	
DSS-003USC1	Systems and Methods for Performing Biological Assays	17/342533	08-Jun-2021	
DSS-003WOUS	Systems and Methods for Performing Biological Assays	16/081793	31-Aug-2018	11123736
31210-31103/US	Devices and Methods for Biological Assay Sample Preparation and Delivery	62/307876	14-Mar-2016	
DSS-004USD1	Devices and Methods for Biological Assay Sample Preparation and Delivery	17/393398	03-Aug-2021	
DSS-004WOUS	Devices and Methods for Biological Assay Sample Preparation and Delivery	16/081799	31-Aug-2018	11125661
31210-32756/US	Selectively Vented Biological Assay Devices and Associated Methods	62/307886	14-Mar-2016	
DSS-005USC1	Selectively Vented Biological Assay Devices and Associated Methods	17/677999	22-Feb-2022	
DSS-005WOUS	Selectively Vented Biological Assay Devices and Associated Methods	16/081802	31-Aug-2018	11291995
DSS-006CID1	Image-Based Disease Diagnostics Using a Mobile Device	18/364401	02-Aug-2023	
DSS-006US	Image-Based Disease Diagnostics Using a Mobile Device	16/155829	09-Oct-2018	11080848
DSS-006USC1	Image-Based Disease Diagnostics Using a Mobile Device	17/364773	30-Jun-2021	
31210-31104/US	Devices and Methods for Modifying Optical Properties	62/307881	14-Mar-2016	
DSS-007WOUS	Devices and Methods for Modifying Optical Properties	16/081800	31-Aug-2018	
DSS-008DUS	Medical Testing Device	29/674581	21-Dec-2018	D907232
DSS-008DUSC1	Medical Testing Device	29/759253	20-Nov-2020	D955598
DSS-009DUS	Test Tube	29/674582	21-Dec-2018	D910200
DSS-010	Multiplexed Biological Assay Device with Electronic Readout	16/185314	09-Nov-2018	10549275

Schedule A of Patent Rights Assignment
between Lucira Health, Inc. and Pfizer Inc.

Attorney Docket No.	Title	Application No.	Filing Date	Patent No.
DSS-010C2	Multiplexed Biological Assay Device with Electronic Readout	17/962324	07-Oct-2022	
31210-38200/US	Multiplexed Biological Assay Device with Electronic Readout	62/558815	14-Sep-2017	
DSS-010USC1	Multiplexed Biological Assay Device with Electronic Readout	16/722475	20-Dec-2019	11465142
DSS-011PR	Bubble-Free Liquid Filling of Fluidic Chambers	62/814143	05-Mar-2019	
DSS-011WOUS	Bubble-Free Liquid Filling of Fluidic Chambers	17/436903	07-Sep-2021	
DSS-012PR	Streamlined Assay Preparation	63/075086	04-Sep-2020	
DSS-012WOUS	Streamlined Assay Preparation	18/024245	01-Mar-2023	
DSS-013PR	Systems and Methods for Performing Biological Assays Using a Thermally Sealed Valve	63/351427	12-Jun-2022	
DSS-014DUS	Assay Device with LCD Display	29/736854	03-Jun-2020	D962470
DSS-015DUS	Diagnostic Device with LED Display	29/733684	05-May-2020	D953561
DSS-015DUSD1	Diagnostic Device with LED Display	29/835658	20-Apr-2022	

[Remainder of page intentionally left blank]

Schedule A of Patent Rights Assignment
between Lucira Health, Inc. and Pfizer Inc.